Podcasts

PsA Podcast: Bimekizumab: Efficacy, safety, and effectiveness in PsA

Join Professors Peter Nash, Philip Mease, and Laura Coates as they discuss the top publications in the world of PsA. This month, the conversation covered a matching-adjusted indirect comparison (MAIC) to assess the comparative efficacy of bimekizumab and risankizumab in patients with psoriatic arthritis over 52 weeks, and a post hoc analysis investigating the efficacy and safety of bimekizumab in PsA patients with or without concomitant methotrexate over 52 weeks.

Discussing RA: Long-term safety and efficacy of upadacitinib in SELECT trials

Join Professor Iain McInnes and Professors Hideto Kameda and Rieke Alten for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA.

In this episode, they discuss two papers which investigate the long-term efficacy and safety of upadacitinib in the SELECT trials.

Discussing AxSpA: Incidence of uveitis following bimekizumab treatment

Join us for the latest axSpA podcast brought to you by the Immune-Mediated Inflammatory Disease Forum! This month, Dr Sofia Ramiro is joined by Professors Hideto Kameda, Atul Deodhar, and Xenofon Baraliakos to discuss a recent study on the incidence of uveitis in patients with axSpA that were treated with bimekizumab.

Author Interview: Professor Laura Andreoli, 2024

Join Professor Peter Nash from the Griffith University in Brisbane, and Professor Laura Andreoli, a Professor of Rheumatology at the University of Brescia, as they discuss her recent paper ‘The outcomes of children born to mothers with autoimmune rheumatic diseases’, published in The Lancet. Rheumatology on 11th June 2024.

Discussing RA: Neutrophil-to-lymphocyte ratio and treatment response to filgotinib

Join Professor Iain McInnes and Professors Hideto Kameda and Peter Nash for the latest episode on The Immune-Mediated Inflammatory Disease Forum, where they discuss the latest information and data in RA.

In this episode, they discuss a paper that investigated whether the baseline neutrophil-to-lymphocyte ratio had an effect on the treatment response to filgotinib.

Author Interview: Dr Adam Goldman, 2024

Join Professor Peter Nash from the Griffith University in Brisbane, and Dr Adam Goldman, an epidemiology researcher at The Chaim Sheba Medical Center in Tel-Hashomer, and an epidemiology researcher and lecturer at Tel-Aviv University, as they discuss his recent paper ‘Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports’, published in Seminars in Arthritis and Rheumatism on 17th May 2024.